Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

527
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
527
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

921
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
921

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Hypoxia promotes BCMA loss and a suppressive secretome thereby hindering CAR T cell therapy in multiple myeloma.

Experimental hematology & oncology·2026
Same author

Preclinical development and selection of nanobody-based CAR-T cells targeting HER2-positive solid tumors.

Molecular therapy. Oncology·2025
Same author

B7-H3 nanobody-based CAR T cells control multiple myeloma growth, while dual BCMA/B7-H3 CAR T cells overcome antigen escape.

Journal of hematology & oncology·2025
Same author

Lipid nanoparticles as a tool to dissect dendritic cell maturation pathways.

Cell reports·2025
Same author

Immune modulation following α and β<sup>-</sup> radionuclide therapy targeting fibroblast activation protein-α in a preclinical tumor model.

Oncoimmunology·2025
Same author

Sequence simplification of antigen coding IVT mRNA allows accelerated synthetic DNA template generation and epitope immunogenicity validation.

Molecular therapy. Nucleic acids·2025

相关实验视频

Updated: Jul 5, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

325

应用免疫检查点阻断剂的新技术.

Robin Maximilian Awad1, Karine Breckpot1

  • 1Laboratory for Molecular and Cellular Therapy, Department of Biomedical Sciences, Vrije Universiteit Brussel, Brussels, Belgium.

International review of cell and molecular biology
|January 15, 2024
PubMed
概括

免疫检查点抑制剂 (ICI) 与单克隆抗体 (mAbs) 一样,可以对抗癌症,但也有缺点. 新的药物交付策略和药物类别正在出现,以提高疗效和减少副作用.

科学领域:

  • 在瘤学瘤学.
  • 免疫学 免疫学 免疫学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 癌细胞通过上调抑制性免疫检查点 (ICP) 蛋白质来逃避免疫检测,导致免疫疲劳和瘤生长.
  • 针对ICPs的单克隆抗体 (mAbs) 通过防止免疫衰竭,彻底改变了癌症免疫疗法.
  • 目前的ICP疗法面临挑战,包括系统管理问题,如不良事件,不良的药理动力学,有限的瘤透率和免疫性.

研究的目的:

  • 审查目前免疫检查点抑制剂 (ICP) 药物输送的最新情况.
  • 探索ICP的新型输送策略和药物类别,以克服当前mAb疗法的局限性.
  • 突出围口传递的进步和新的ICP药物配方.

主要方法:

  • 对当前和新兴的ICP药物输送策略的文献综述.
  • 分析了与ICP单克隆抗体 (mAbs) 系统注射相关的缺点.
  • 探索新的输送技术和新的ICP药物类别.

主要成果:

  • 系统的mAbs给药会导致不良事件,不良的药理动力学和瘤的有限可访问性.
  • 周围口输送和新型药物类别为当前的ICP治疗局限性提供了潜在的解决方案.
  • 新的输送技术正在开发中,以提高ICP药物的有效性和安全性.
关键词:
管理路线的管理路线.细胞疗法是一种细胞疗法.细胞毒性T淋巴细胞抗原-4基因治疗是一种基因疗法.抑制性免疫检查点 抑制性免疫检查点单克隆抗体是一种单克隆抗体.一个纳米人体.纳米医学是一种纳米医学.编程细胞死亡蛋白-1-1编程死亡联手 1 编程死亡联手 1

更多相关视频

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.7K
Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

779

相关实验视频

Last Updated: Jul 5, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

325
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.7K
Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

779

结论:

  • 新的输送策略和药物类别对于推进免疫检查点抑制剂治疗至关重要.
  • 通过创新的输送方法来解决当前mAb疗法的局限性,可以改善癌症治疗结果.
  • 该领域正在朝着更有针对性和有效的ICP药物供应迈进,以增强抗瘤免疫力.